# ROUND 316 AUDIT — Parameter Uncertainty, P-20 Manufactured, Portfolio Table

**Round:** 316
**Date:** 2026-08-26
**Remote HEAD:** (R316 pending push)
**Authority:** CEO R316; Articles XXVII–XXXVI

---

## 1. P-19 parameter uncertainty — PASS (robust across 200 LHS samples)

Per CEO R316 §1: "Test whether the mechanism survives realistic uncertainty in the SYSTEM, not merely the acceptance cutoff."

**200 LHS samples** varying: Q_production (0.20-0.40), compliance (0.10-0.50), obstruction rate (0.5-2.0x), control latency (0-60s), obstruction location (random 7 of 10).

**Results at MODELLED_ENGINEERING_THRESHOLD (25 mmHg):**
- Distributed median survival: 48.0h (survives full duration in ALL 200 samples)
- Distributed 5th percentile: 48.0h
- Single-segment median: 40.4h
- Single-segment 5th percentile: 25.0h
- Effect size median: 7.6h (95% CI: [5.7, 8.8])
- **Verdict: PASS** — distributed robust to parameter uncertainty, single-segment degrades

**Key finding:** Distributed system survives 48h in every single parameter combination. The 10-segment redundancy provides enough resilience that parameter variations (CSF production, compliance, obstruction pattern) don't cause failure. Single-segment varies (25-48h) — it's sensitive to the same parameters.

**Sensitivity analysis:** Spearman correlations are NaN because distributed survival is constant (all 48h). This is itself a finding — the distributed architecture is robust to all tested parameter variations.

## 2. P-20 manufactured — PASS (IL-10 release sustained 30 days)

Per CEO R316 §5: "Manufacture: mechanism model, comparator, kinetics, attack suite, falsification criterion, uncertainty, sensitivity, repair budget, reproducible package."

**Mechanism:** Dual — (A) synthetic CD47-mimetic glycan surface (5×10¹² molecules/cm²) + (B) IL-10 analog released from PLGA polymer matrix (0.5 mg/cm² loading, 7-day half-life, inflammation-proportional feedback).

**Falsification test:** IL-10 release ≥ 0.1 ng/cm²/day sustained 30 days AND glycan density ≥ 10¹²/cm².
- **IL-10 release day 30:** 2468 ng/cm²/day (24,680× above threshold)
- **Glycan density:** 5×10¹²/cm² (5× above threshold)
- **Attack suite:** 4/4 survived (PLGA rapid degradation, chronic inflammation, glycan shedding, IL-10 denature)
- **Verdict: PASS**

**Label:** MANUFACTURED — IL-10 kinetics MODELLED (PLGA degradation from published data) — wet-lab validation required.

## 3. svFSI — EXTERNAL_SOLVER_UNAVAILABLE (honest)

Per CEO R316 §2: "Do not convert could not run into verified."

All 4 pathways attempted and failed:
- Precompiled .deb: no root
- Docker: not installed
- Source build: cmake now available (pip), but MPI+PETSc still missing (need root for `apt install`)
- pip: not available

**Label:** `EXTERNAL_SOLVER_UNAVAILABLE`. Reproducible package preserved (svFSI pipe3D_RCR test case + parameter-matched 1D model) for execution when environment permits.

**Impact:**
- P-01 blocked at MODEL_ATTACKED (cannot do 3D physics verification)
- P-19 blocked at TECHNICALLY_EVALUABLE (cannot do external solver cross-check)
- 0/15 candidates can achieve actual external solver verification while this constraint persists

## 4. Portfolio state table (mechanically generated)

| State | Count |
|-------|------:|
| MODEL_RUNNING | 10 |
| MODEL_ATTACKED | 2 (P-01, P-20) |
| MODEL_INDEPENDENTLY_VERIFIED | 2 (P-15, P-16) |
| TECHNICALLY_EVALUABLE | 1 (P-19) |
| TECHNOLOGY_TRANSFER_READY | **0** |
| BUYER_TESTED | 0 (CEO-owned) |

**15 active + 5 cemetery. 0/15 TECHNOLOGY_TRANSFER_READY.**

## 5. What R316 did NOT do

- Did NOT claim P-19 as TECHNOLOGY_TRANSFER_READY (external solver still required)
- Did NOT tune P-01's model further (per CEO §3: "no more manual coefficient adjustment")
- Did NOT convert "could not run" into "verified" (per CEO §2)
- Did NOT invent P-21 (per CEO §5)
- Did NOT create new framework (per CEO: "execution round, not framework round")

## 6. R317 priorities

1. **CEO action:** Provide Docker or root access for svFSI. This is the single unblock that would move P-19 from TECHNICALLY_EVALUABLE to TECHNOLOGY_TRANSFER_READY.
2. **P-10/P-14/P-17 repair:** Each has one repair budget. Diagnose mechanism vs implementation, attempt repair, retest or cemetery.
3. **Phase B acceleration:** P-02, P-04, P-11, P-12 — move from MODEL_RUNNING to MODEL_ATTACKED (run attack suites).
4. **P-19 economics completion:** Economics MODELLED but needs full TTP economics package with evidence tiers.
5. **P-15/P-16 TTP assembly:** Both independently verified but TTP not assembled.

## 7. The CEO test (R316 honest answer)

> Could you take any one of the 15 folders tomorrow, hand it to a competent engineering team?

- **P-19:** APPROACHING YES — TTP assembled, metric robust (6/6 thresholds + 200 LHS samples), but external solver pending
- **P-15:** APPROACHING YES — buyer envelope complete
- **P-16:** PARTIAL YES — external MC verified, TTP pending
- **P-20:** NO — just manufactured, needs independent verification + economics + TTP
- **P-01:** NO — 3D physics blocked
- **10 others:** NO — MODEL_RUNNING, not yet attacked

**R316 progress:** P-19 parameter uncertainty tested (robust). P-20 manufactured (PASS). Portfolio table mechanically generated. svFSI honestly labeled EXTERNAL_SOLVER_UNAVAILABLE. No semantic inflation. No framework creation.
